[HTML][HTML] Hypomethylating agents (HMA) for the treatment of acute myeloid leukemia and myelodysplastic syndromes: mechanisms of resistance and novel HMA-based …
J Stomper, JC Rotondo, G Greve, M Lübbert - Leukemia, 2021 - nature.com
Aberrant DNA methylation plays a pivotal role in tumor development and progression. DNA
hypomethylating agents (HMA) constitute a class of drugs which are able to reverse DNA …
hypomethylating agents (HMA) constitute a class of drugs which are able to reverse DNA …
American Society of Hematology 2020 guidelines for treating newly diagnosed acute myeloid leukemia in older adults
MA Sekeres, G Guyatt, G Abel, S Alibhai… - Blood …, 2020 - ashpublications.org
Background: Older adults with acute myeloid leukemia (AML) represent a vulnerable
population in whom disease-based and clinical risk factors, patient goals, prognosis, and …
population in whom disease-based and clinical risk factors, patient goals, prognosis, and …
Discovery of a first-in-class reversible DNMT1-selective inhibitor with improved tolerability and efficacy in acute myeloid leukemia
MB Pappalardi, K Keenan, M Cockerill, WA Kellner… - Nature cancer, 2021 - nature.com
DNA methylation, a key epigenetic driver of transcriptional silencing, is universally
dysregulated in cancer. Reversal of DNA methylation by hypomethylating agents, such as …
dysregulated in cancer. Reversal of DNA methylation by hypomethylating agents, such as …
Oral cedazuridine/decitabine for MDS and CMML: a phase 2 pharmacokinetic/pharmacodynamic randomized crossover study
G Garcia-Manero, EA Griffiths… - Blood, The Journal …, 2020 - ashpublications.org
This phase 2 study was designed to compare systemic decitabine exposure, demethylation
activity, and safety in the first 2 cycles with cedazuridine 100 mg/decitabine 35 mg vs …
activity, and safety in the first 2 cycles with cedazuridine 100 mg/decitabine 35 mg vs …
Precision medicine treatment in acute myeloid leukemia using prospective genomic profiling: feasibility and preliminary efficacy of the Beat AML Master Trial
A Burd, RL Levine, AS Ruppert, AS Mims, U Borate… - Nature medicine, 2020 - nature.com
Acute myeloid leukemia (AML) is the most common diagnosed leukemia. In older adults,
AML confers an adverse outcome,. AML originates from a dominant mutation, then acquires …
AML confers an adverse outcome,. AML originates from a dominant mutation, then acquires …
Magrolimab in combination with azacitidine in patients with higher-risk myelodysplastic syndromes: final results of a phase Ib study
DA Sallman, MM Al Malki, AS Asch… - Journal of Clinical …, 2023 - ingentaconnect.com
PURPOSE Magrolimab is a monoclonal antibody that blocks cluster of differentiation 47, a
don't-eat-me signal overexpressed on cancer cells. Cluster of differentiation 47 blockade by …
don't-eat-me signal overexpressed on cancer cells. Cluster of differentiation 47 blockade by …
[HTML][HTML] Biologic assignment trial of reduced-intensity hematopoietic cell transplantation based on donor availability in patients 50-75 years of age with advanced …
R Nakamura, W Saber, MJ Martens… - Journal of clinical …, 2021 - ncbi.nlm.nih.gov
PURPOSE Allogeneic hematopoietic cell transplantation (HCT) is the only potentially
curative therapy for myelodysplastic syndromes (MDS), although it is infrequently offered to …
curative therapy for myelodysplastic syndromes (MDS), although it is infrequently offered to …
Diagnosis and treatment of primary myelodysplastic syndromes in adults: recommendations from the European LeukemiaNet
L Malcovati, E Hellström-Lindberg… - Blood, The Journal …, 2013 - ashpublications.org
Within the myelodysplastic syndrome (MDS) work package of the European LeukemiaNet,
an Expert Panel was selected according to the framework elements of the National Institutes …
an Expert Panel was selected according to the framework elements of the National Institutes …
Myelodysplastic syndromes, version 2.2017, NCCN clinical practice guidelines in oncology
PL Greenberg, RM Stone, A Al-Kali, SK Barta… - Journal of the National …, 2017 - jnccn.org
The myelodysplastic syndromes (MDS) comprise a heterogenous group of myeloid
disorders with a highly variable disease course. Diagnostic criteria to better stratify patients …
disorders with a highly variable disease course. Diagnostic criteria to better stratify patients …
Myelodysplastic syndromes: 2018 update on diagnosis, risk‐stratification and management
G Montalban‐Bravo… - American journal of …, 2018 - Wiley Online Library
Disease overview The myelodysplastic syndromes (MDS) are a very heterogeneous group
of myeloid disorders characterized by peripheral blood cytopenias and increased risk of …
of myeloid disorders characterized by peripheral blood cytopenias and increased risk of …